Long-term survival among colorectal cancer patients in Finland, 1991–2015: a nationwide population-based registry study

Abstract

Background Colorectal cancer (CRC) incidence in Finland has risen steadily. Given development in cancer treatments in recent decades, disease-specific data on the long-term prognosis of patients may be obsolete. Thus, this study aimed to report 5-year disease-specific survival (DSS) and relative survival based on tumour spread and site among CRC patients diagnosed between 1991 and 2015 in Finland. Material and methods We conducted a population-based registry study among 59 465 CRC patients identified from the Finnish Cancer Registry. Results The 5-year DSS for all CRC patients was 56.7% [95% confidence interval (CI) 56.3–57.1%] for 1991 through 2015. Tumour site-specific survival has improved for the period 2006–2015 versus 1991–2005 for right-sided colon cancer from 54.8% (95% CI 53.8–55.8%) to 59.9% (95% CI 58.7–61.1%), for left-sided colon cancer from 54.1% (95% CI 52.9–55.3%) to 61.0% (95% CI 59.8–62.2%) and for rectal cancer from 53.6% (95% CI 52.2–55.0%) to 62.3% (95% CI 61.3–63.3%). The 5-year relative survival for the period 2006 through 2015 was 93.6% for localised disease (stage I); 84.2% for locally advanced tumour invading adjacent structures (stage II); 68.2% for regional disease with regional lymph node metastases (stage III); and 14.0% for metastatic disease (stage IV). Conclusions This study confirms that survival for CRC has improved in recent decades in Finland, mirroring observations from other Western countries. However, the classification of tumour spread within the Finnish Cancer Registry differs slightly from the TNM classification, thereby limiting the generalisability of these results.

Mean platelet volume/platelet count ratio in combination with tumor markers in colorectal cancer: a retrospective clinical study

“…Most CRCs develop through the adenoma-carcinoma sequence, and the progression is relatively slow (10 to 15 years) [ 31 ], presenting opportunities to prevent cancer by removing its precursor lesions, in addition to identifying CRC in its earliest, curable stages. Relevant studies suggest that the earlier CRC or precancerous lesions are detected, the higher the survival rate of patients [ 32 ]. Yet, the majority of CRC is sporadic and largely attributable to the constellation of modifiable environmental risk factors characterizing westernization (for example, obesity, physical inactivity, poor diets, et al).…”

Survival outcomes of stage I colorectal cancer: development and validation of the ACEPLY model using two prospective cohorts

“…As opposed to the European population [ 35 ], rectal cancer tends to be more dominant in eastern Asia. In accordance with our results, a reported 50 ~ 80% of CRC patients presented rectal tumors in China [ 30 , 36 ].…”

HNRNPA2B1 mediated MircoRNA-92a upregulation and section acts a promising non-invasive diagnostic biomarker in colorectal cancer

“…Numerous primary and secondary studies have found that early detection and diagnosis will decrease CRC-speci c mortality compared with no screening [41]. However, due to invasiveness, associated costs and stigma, colonoscopy is often refused by patients and postponing this investigation can have a devastating impact on outcomes once diagnosed.…”